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Abstract 
Increased interest in vitamin D measurements in clinical studies has contributed to the development in recent years of several new im-
munochemical assays (manual and for automatic analyzers). New methods, including HPLC (high performance liquid chromatography), 
and LC-MS/MS (liquid chromatography coupled with tandem mass spectrometry) have also been introduced into routine diagnostic 
laboratories. Because of the variety of assays and methods used, the question arises which one is the most accurate for the measurement 
of vitamin D metabolites concentration. In this review, we summarise the advantages and disadvantages of these methods, describe 
the complexity of vitamin D metabolites pattern in the circulation, and discuss the problem of accurate measuring its concentration. 
(Endokrynol Pol 2013; 64 (3): 238–245)
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Streszczenie
Wzrost zainteresowania oznaczeniami stężenia witaminy D przyczynił się do opracowania w ostatnich latach nowych testów immuno-
chemicznych (manualnych oraz do automatycznych analizatorów). Do laboratoriów diagnostycznych wprowadza się również techniki 
dotychczas niestosowane w rutynowych oznaczeniach witaminy D, takie jak HPLC (wysokosprawna chromatografia cieczowa) oraz 
LC-MS/MS (tandemowa spektrometria mas sprzężona z wysokosprawną chromatografią cieczową). W związku z różnorodnością testów 
i metod pojawia się pytanie o ich wiarygodność. W niniejszej pracy przeglądowej opisano występujące w krwiobiegu metabolity witaminy 
D, przedstawiamy zalety i wady stosowanych metod oznaczania ich stężenia oraz omawiamy czynniki mające wpływ na wiarygodność 
wyników tych oznaczeń.  (Endokrynol Pol 2013; 64 (3): 238–245)
Słowa kluczowe: witamina D, kalcydiol, kalcytriol, testy immunochemiczne, LC-MS/MS
Introduction
The high interest in vitamin D due to the important, 
complex, pleiotropic role it plays in the human body 
and the consequences of its insufficiency for our health 
have resulted in a dramatic increase in vitamin D me-
tabolite concentration measurements [1–4]. It is believed 
that vitamin D status in humans is best reflected by the 
concentration of its 25-hydroxylated isoforms (25(OH)
D, calcidiol) which are the most frequently assessed 
vitamin D metabolites, whereas the measurement of 
1,25-dihydroxylated forms (1,25(OH)2D, calcitriol) are 
of limited use [5, 6]. A variety of vitamin D metabolites 
appear in the circulation, and the different assays and 
methods used for its determination affect the accuracy 
of the results obtained. This issue, of great importance 
for clinical practice, we would like to discuss in this 
article.
The variety of vitamin D metabolites  
in the circulation
Vitamin D occurs in nature in two chemical forms: vita-
min D2 and D3 which differ in a double bond between 
carbon atoms 22 and 23 and a methyl group at carbon 
atom 24 (Fig. 1). In humans, the most common form is 
vitamin D3, mainly synthesised during skin exposure to 
UV rays of sunlight, which constitute up to 90% of the 
total vitamin D body pool [7, 8]. Casual UVB irradiance 
in summer can generate 1,000–2,000 IU/day of vitamin 
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D3 [8]. It can be also supplied with food of animal origin 
(mostly wild, oily fish) [9]. Vitamin D2 is synthesised by 
plants, yeast and mushrooms and delivered with diet 
[10, 11]. Both D2 and D3 can be administered to patients 
as a drug in a case of vitamin D insufficiency. In people 
ingesting a high amount of D2, the ratio of D3 to D2 can 
be substantially different from the average found in 
the population.
Vitamin D produced or taken with the diet is trans-
ported to the liver, and its excess is stored in fat tissue 
and muscle. The storage of vitamin D3 in fat tissue con-
siderably extends its half-life to as much as two months, 
whereas in plasma it lasts 2–3 days (Table I). The plasma 
half-life of vitamin D2 is shorter because of its low af-
finity to specific transporting protein VDBP (vitamin 
D binding protein) protecting bound fraction against 
metabolism and excretion [12]. To achieve biological 
activity, vitamin D2 and D3 have to be hydroxylated, 
first in the liver to 25-hydroxylated metabolites 25(OH)
D2 and 25(OH)D3 (calcidiol), then in the kidney (1a-
hydroxylation) into vitamin D most biologically active 
calcitriol: 1,25(OH)2D2 and 1,25(OH)2D3 (Fig. 2) [6, 7, 13]. 
Synthesis of calcitriol is controlled in the kidney by a 
negative feedback mechanism protecting against exces-
sive hydroxylation at the carbon atom C-1. High level 
of calcitriol inhibits the synthesis of PTH (parathyroid 
hormone) on genetic level. A diminished concentration 
of PTH decreases 1a-hydroxylase activity, and in that 
way synthesis of calcitriol. In addition, reabsorption of 
phosphates increased by calcitriol causes an enhanced 
release of FGF-23 (fibroblast growth factor 23) which 
activates 24-hydroxylase, leading to the synthesis of 
24,25(OH)2D in the kidney — the first step of inactiva-
tion and removal of vitamin D from the circulation (Fig. 
2). Although 24,25(OH)2D is usually considered as an 
inactive metabolite, it plays an important role in the 
maturation and growth of cartilage [14, 15]. In the next 
step, water-soluble calcitroic acid is produced and ex-
creted in bile. The vitamin D metabolites hydroxylated 
at C-23 or C-26 are also found in blood [13]. 
The variety of vitamin D metabolites in the circu-
lation is further increased by two natural processes: 
epimerisation and lactonisation. Epimerisation of vita-
min D metabolites is the process of enzymatic conver-
sion around the asymmetric carbon atom, which does 
not change molecular weight and atoms sequence, 
the only difference being stereo configuration. Carbon 
atom C-3 is a potential epimerisation centre for 25(OH)
D, 1,25(OH)2D and other vitamin D metabolites. The 
C-3b-hydroxyl vitamin D metabolites that are syn-
thesised in nature are converted into the correspond-
ing C-3a-hydroxyl epimers (C3-epimers) by specific 
epimerases located in the cytosolic fraction of the liver 
and locally in cells (e.g. keratocytes, macrophages). 
Epimerisation influences the chemical and biological 
activity of vitamin D metabolites [16, 17]. Both a and b 
C3-epimers of vitamin D can be further hydroxylated 
in the kidney [18]. Another structural change of vitamin 
D is lactonisation with the formation of additional ring 
structure between C-23 and C-26 [19, 20]. The side chain 
modificated lactones act as partial agonists of vitamin 
D receptor (VDR) and may modulate its activity [21].
Because of high hydrophobicity, the vitamin D 
metabolites are poorly soluble in aqueous media, and 
similarly to the thyroid and steroid hormones, are 
transported in blood in bound form – mostly to specific 
carrier protein VDBP and loosely bound to albumin 
(Table I). Free 25(OH)D3 and 1,25(OH)2D3 forms in 
blood account for about 0.03–0.4% and 0.4%–2% of 
the total metabolite respectively. The level of unbound 
1,25(OH)2D is well correlated with its biological activity, 
which suggests that the free hormone hypothesis may 
apply to the vitamin D system [12]. However, methods 
permitting the direct measurement of free fractions of 
25(OH)D or 1,25(OH)2D for diagnostic purposes are 
unknown.
Binding to the blood components ensures the vita-
min D metabolites high stability in serum and plasma 
[22]. They are stable even for several days when kept 
at room or increased temperature, and are unaffected 
either by light facilities or multiple freeze-thaw cycles 
[23], but caution has to be paid when vitamin D is re-
leased from VDBP and separated from blood because 
such samples are light- and temperature-sensitive [24, 
25]. This applies to some vitamin D standards and 
Figure 1. Chemical structure of vitamin D3 (cholecalciferol) 
and vitamin D2 (ergocalciferol) with marked carbon atoms 
undergoing hydroxylation. Carbon atom C-3 is a potential centre 
for epimerisation
Rycina 1. Struktura chemiczna witaminy D3 (cholekalcyferol) i 
D2 (ergokalcyferol) z zaznaczonymi atomami węgla podlegającymi 
hydroksylacji. Atom węgla C-3 stanowi potencjalne centrum 
epimeryzacji
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samples extracted for HPLC and LC-MS/MS analysis 
which should be kept in amber tubes or dark glass vi-
als at –70°C.
Clinical usefulness of vitamin D  
metabolite measurements 
Providing the optimal vitamin D supply is essential for 
human health [1, 7, 26]. The role of vitamin D in the 
body is multidirectional [1, 27]. The active metabolite 
1,25(OH)2 D is directly involved in the absorption of 
calcium and phosphate which is important to ensure 
proper bone mineralisation. There are studies indicat-
ing that serum level of 25(OH)D below 20 ng/mL is 
associated with an increased risk of cardiovascular 
disease, some cancers and autoimmune diseases [28, 
29]. Recent reports on the non-classic mechanisms of 
vitamin D action have indicated its physiological role in 
the regulation of innate and acquired immunity [30–32]. 
Vitamin D stimulates the differentiation of monocyte 
Table I. Characteristics of vitamin D3 and its metabolites
Tabela I. Charakterystyka witaminy D3 i jej metabolitów
Parameters D3 25(OH)D3 1,25(OH)2D3
Concentration in plasma 0.4–2.8 ng/mL 8–56 ng/mL
(winter up to 24 ng/mL)
16–65 pg/mL
Half life in plasma 36–78 hr 15–25 days 3.5–21 hr
Affinity to Calcitroic acid Ka = 500–700 uM
-1 Ka = 40 uM
-1
Affinity to albumin Ka = 0.6 uM
-1 Ka = 0.054 uM
-1
Bound to VDBP (%) 85–99% 60–85%
Bound to albumin (%) 13–15% 38%
Free fraction (%) 0.03–0.4% 0.4–2%
Affinity to VDR Ka = 0,6 uM
-1 Ka = 10
4–105 uM–1
Figure 2. Synthesis and metabolism of vitamin D
Rycina 2. Synteza i metabolizm witaminy D
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precursors to more mature phagocytic macrophages 
and, by binding to the toll-like receptor (TLR2), the 
main receptor recognising pathogens, can stimulate 
the expression of the antibacterial protein cathelicidin. 
The stimulatory effect of vitamin D in the response to 
infection or inflammation has been demonstrated in 
many diseases such as tuberculosis, multiple sclerosis, 
Crohn’s disease, type 1 diabetes, E. coli infection of the 
liver, malaria and typhoid [31].
The above examples unequivocally show the im-
portance of optimal vitamin D supply which can be 
achieved by exposure to the sun, proper diet or sup-
plementation with pharmaceutical preparations [33, 
34]. Vitamin D status greatly depends on factors such 
as food habits, genetic factors, climatic conditions de-
termining the skin synthesis and the cultural habits of 
exposing the body to sunlight (especially in women) 
[35, 36]. According to international and Polish recom-
mendations, the optimal serum level of 25(OH)D is 
above 30 ng/mL for adults and 20 ng/mL for children 
(Table II) [6, 11, 33, 34]. Population studies clearly show 
that vitamin D insufficiency is a global epidemic, as well 
as being widespread in the Polish population [33, 34].
Choosing the best metabolite for assessing  
the body storage of vitamin D 
Vitamin D status in the human body is best reflected by the 
total concentration of its 25-monohydroxylated isoforms: 
25(OH)D3 and 25(OH)D2 [5, 6, 37]. The determination of 
the 25(OH)D is of great importance since it detects both 
a shortage of vitamin D and its overdosing in a case of 
poorly controlled supplementation [3, 26, 40].
Although 1,25(OH)2D is the active form of hormone, its 
short half-life, significant dependence on renal failure, and 
low concentration in plasma (more than 1,000 times lower 
compared to 25(OH)2D) bring about technical challenges 
and then the limited usefulness of its measurement [12]. 
This parameter is not useful in vitamin D deficiency moni-
toring because, even in severe vitamin D deficiency, this 
parameter may still remain in the reference range. However, 
monitoring of 1,25(OH)2D can be useful in rare cases of renal 
and hepatic failure and suspected vitamin D resistance or 
acquired and inherited disorders of 1,25(OH)2D metabolism 
[37]. The concentration of vitamin D3 and D2 in plasma is 
diet- and supplementation-dependent, and highly affected 
by skin synthesis [12]. Attempts to determine the D3 level 
in human fat tissue have also been described [38]. A higher 
concentration of D3 in adipose tissue has been found in 
obese compared to normal weight people, although this 
analysis has no practical value [39]. 
Clinical reasons for vitamin D measurement
Vitamin D measurements are useful in the following 
clinical situations [1–6, 32, 41–43]:
Osteoporosis. Vitamin D is the only accessible hor-
mone affecting the expression of calbindin in the gut 
which is responsible for the active absorption of calcium 
from the lumen of jejunum. The reduction of muscle 
strength and increased risk of falls with bone fracture 
is directly related to a vitamin D deficiency.
Disorders of malabsorption. Disorders of the ab-
sorption such as Crohn’s disease, coeliac disease or 
gut amyloidosis (involving the proximal part of the 
jejunum) lead to impaired absorption of calcium and 
chylomicrons containing vitamin D3.
Pregnancy. The metabolism of pregnant woman 
is related to the development of the foetus. Placental 
secretion of PTHrP (PTH-related protein) causes the 
transport of calcium ions against the natural gradi-
ent from mother to child. The increased demand for 
calcium increases absorption of this ion in the diges-
tive tract. This adaptation requires the proper supply 
of vitamin D. Moreover, the correct concentration 
of vitamin D during pregnancy independently of 
other factors reduces the risk of diabetes and pre-
eclampsia [44–46]. 
Table II. Frequently used cut-points for vitamin D status [3, 11, 34]
Tabela II. Wartości odcięcia używane najczęściej dla oceny statusu witaminy D [3, 11, 34]
Classification 25(OH)D 
ng/mL*
25(OH)D 
nmol/L*
Toxic level > 100 > 250
Sufficiency or optimal level 30–80 in adults
20–60 in children
75–200 in adults
50–150 in children
Insufficiency 20–30 in adults
10–20 in children
50–75 in adults
25–50 in children
Deficiency 10–20 in adults 25–50 in adults
Severe deficiency < 10 < 25
*Conversion factors for 25(OH)D: nmol/L x 0.40 = ng/mL (ng/mL = ug/L); ng/mL x 2.50 = nmol/L
242
The measuremant of vitamin D metabolites  Zbigniew Bartoszewicz et al.
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
Calcium and phosphate balance. It is now generally 
accepted that 25(OH)D should be measured in patients 
with primary hyperparathyroidism; balanced metabo-
lism of vitamin D lowers the level of PTH and reduces 
the risk of  ‘hungry bones syndrome’ after surgical treat-
ment of primary hyperparathyroidism. An indication to 
measure calcitriol is primarily a differential diagnosis of 
hypercalcaemia due to the ability of certain granulomas 
to perform hydroxylation of vitamin D at C-1. 
Renal failure. Renal failure leads to lowering of 
1,25(OH)2D due to impaired 1a-hydroxylation. 
Rickets and osteomalacia. Testing of vitamin D 
status is used in differential diagnosis of rickets and 
osteomalacia (deficiency of vitamin D, the resistance 
of the receptor for vitamin D, hypophosphataemic 
rickets). Low calcitriol can be observed in vitamin D-
dependent rickets type I (inborn reduction of 25(OH)
D to 1,25(OH)2D conversion), whereas its high level 
accompanies D-dependent rickets type II (inborn defect 
of 1,25(OH)2D recognition by target tissue).
Monitoring of vitamin D supplementation, espe-
cially when applying vitamin D2. Due to the moderate 
affinity to VDBP, 25(OH)D2 has a shorter half-life in 
serum than 25(OH)D3 and consequently may be less 
biologically active. Monitoring the supplementation 
can be crucial in patients with intestinal malabsorption, 
severe hepatic failure or who are at higher risk of vita-
min D deficiency (e.g. very young and elderly people).
Other diseases. Low 25(OH)D concentration may 
be associated with cardiovascular events, hyperten-
sion, metabolic syndrome, high blood sugar and other 
chronic diseases. Optimal vitamin D level improves 
the outcome in critically ill patients. There is no justi-
fication for the determination of vitamin D in order to 
determine the risk of any cancer, despite statistical data 
showing the influence of vitamin D on improving im-
munological response and reducing the risk of cancer. 
Overview of methods used to measure  
the vitamin D metabolites concentration 
Many methods are used to measure vitamin D me-
tabolites concentration in serum or plasma. The most 
popular are immunoassays, but due to unsatisfactory 
results of inter-laboratory quality control programmes, 
new methods including HPLC, GC-MS and LC-MS/ 
/MS are being introduced into routine diagnostic labo-
ratories [47–55].
Immunoassays
The measurement of 25(OH)D concentration. Various 
formats of vitamin D immunoassays for the measurement 
of 25(OH)D concentration are available, including direct 
immunoassays and preceded by extraction immunoas-
says. All of them encounter methodological problems. 
Firstly, there are two forms of 25(OH)D: 25(OH)D3 
and 25(OH)D2 which differ in their chemical structure 
(Fig. 1) as well as in their affinity to antibodies used in 
the assay (Table III). In consequence, the total concentra-
tion of 25(OH)D measured in a patient’s serum is highly 
dependent on the 25(OH)D3 to 25(OH)D2 ratio and the 
source of antibody used for immunoassay construction 
[49–51]. Furthermore, in some assays VDBP is used in ex-
change for recognising antibody [56]. These are probably 
the most important reasons why it is difficult to compare 
results obtained by various immunoassays. Especially in 
people taking D2 supplementation or being on a diet with 
relatively high vitamin D2 doses (e.g. a vegetarian diet), the 
total 25(OH)D concentration may differ when measured 
with different immunoassays. 
Another problem is the ability of vitamin D immu-
noassays to recognise the C-3 epimers of 25(OH)D. This 
is not a major problem for most adult human samples, 
where C-3 epimers are present in small amounts. Ac-
cording to Lensmeyer et al. [57], in 92% of adult samples 
tested by the most suitable LC-MS/MS method, the 
concentration of 3-epi-25(OH)D3 is 3.0 ng/mL or lower, 
although the authors described some patients where 
3-epi-25(OH)D3 accounted for 25% of the total 25(OH)
D level. In adults, the 3-epi-25(OH)D3 concentration 
is not correlated with age [58] but usually the higher 
the concentration of 25(OH)D3, the higher amount of 
epimer is observed [57]. C-3 epimerisation is a problem 
of infants and mothers in the final stages of pregnancy 
[58, 59]. Total 3-epi-25(OH)D in infants ranged from 5 
ng/mL to 93 ng/mL and contributed to 8.7–61.1% of total 
25(OH)D concentrations [59]. Separate issues are rea-
gents used to block the effect of steroid hormones and 
cross-reactions with compounds structurally related to 
25(OH)D including D2, D3, 1,25(OH)2D2, 1,25(OH)2D3, 
24,25(OH)2D, their lactons and C-3 epimers, which in 
individual patients can lead to false vitamin D results. 
The problems described above make it difficult to 
reliably measure the 25(OH)D concentration by im-
munochemical methods and to establish the precise 
boundaries of vitamin D deficiency. As a consequence, 
the interassay differences have an impact on clinical de-
cision making [52, 53]. For example, out of 494 patients 
examined, 52% were classified as deficient patients by 
DiaSorin Liaison immunoassay, but only 36% when the 
concentration of 25(OH)D was measured by IDS RIA 
test [52]. The significant disparity of 25(OH)D results 
obtained by different immunoassays has also been 
observed in participants of international quality pro-
grammes [51, 55, 56]. The Vitamin D External Quality 
Assessment Scheme (DEQAS) organised in Europe by 
Dr. Carter has compared the accuracy of 25(OH)D meth-
ods over more than two decades. The mean deviation 
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(% bias) from the target value (all laboratory trimmed 
mean) for immunoassays has significantly improved 
over the years, from about 35% to 20%. [51, 54, 56] but 
still the results of 25(OH)D concentration should always 
be interpreted together with other laboratory results 
(concentration of ionised calcium, calcium excretion, 
concentration of phosphates and PTH) and the clinical 
picture of the patient. 
The measurement of 1,25 (OH)2D concentration. 
Although the concentration of 1,25(OH)2D in blood 
is more than three orders of magnitude lower 
compared to 25(OH)2D, in some clinical cases the 
measurement of 1,25(OH)2D concentration can be 
useful. Unfortunately manual, laborious immunoas-
says are the only method applicable so far. All these 
methods are based on the preliminary separation of 
1,25(OH)2D by the use of columns with VDBP. After 
the release of bound vitamin D, the immunoassays 
with antibodies specific to 1,25(OH)2D are used. The 
problem of disparate recognition of 1,25(OH)2D2 and 
1,25(OH)2D3 by different antibodies which affects the 
final result of the assay is the same as in the case of 
25(OH)D measurements.
LC-MS/MS 
Due to the high complexity of instrumental setup and 
high requirements for specialised personnel in the 
diagnostic laboratory, LC-MS/MS has been primarily 
used as a reference method, although great advances in 
equipment automation, increases in staff qualifications 
and the widespread use of mass spectrometry methods 
in other areas have led to increased interest in LC-MS/ 
/MS methods in routine medical diagnostics, as well as 
an attractive alternative to immunoassays in general 
[38, 48, 50, 53, 57–62].
Description of the method. The specificity of 
the LC-MS/MS methods is based on differences in 
molecular masses of analysed substances and their 
characteristic fragments. Additionally, prior to MS 
analysis, all compounds are separated by liquid chro-
matography and distinguished by retention time. In 
order to provide better precision of quantification, 
stable isotope-labelled compounds are used as internal 
standards. For routine quantitative analysis of clinical 
samples, the most commonly used instrumental setup 
is high or ultra performance liquid chromatography 
(HPLC or UPLC) coupled with a triple quadrupole 
 Table III. Cross-reactions (%) of vitamin D2 and D3 metabolites in diagnostic immunoassays used for 25(OH)D measurement. 
Data from manufacturer’s instructions. The cross-reactions with 1,25(OH)2D2 and 1,25(OH)2D3 were not considered, because 
of their irrelevant concentration compared to other vitamin D metabolites
Tabela III. Reakcje krzyżowe (%) metabolitów witaminy D2 i D3 w testach immunochemicznych używanych do diagnostycznych 
pomiarów stężenia 25(OH)D. Nie uwzględniono reakcji krzyżowych dla 1,25(OH)2D2 i 1,25(OH)2D3, ponieważ ich stężenie jest 
nieistotne w stosunku do innych metabolitów witaminy D
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mass spectrometer [62]. The proper choice of ionisation 
method is of great importance for the best sensitivity 
and reproducibility of quantitative determinations. 
Mass spectrometers analyse ions in high vacuum which 
requires evaporation and ionisation of compounds of 
interest. There are three main methods of ionisation 
commonly used in LC-MS/MS. First and most popular 
is ESI (electrospray ionisation). Its advantages are: 
simplicity of operation, very broad dynamic range (up 
to four orders of magnitude), and general availability. 
This mode allows the analysis of compounds of high 
molecular masses (even above 30 kilodaltons) such as 
polypeptides and proteins. For the determination of 
non-polar compounds like vitamin D metabolites and 
some steroid hormones, better results can be achieved 
by two other modes of ionisation: APCI (Atmospheric 
Pressure Chemical Ionisation) and APPI (Atmospheric 
Pressure Photo Ionisation). In those modes, ionisation 
takes place in the gas phase, which limits analysis 
to relatively lower molecular masses (usually below 
1 kilodalton). The most commonly used mode of opera-
tion in quantitative MS is called MRM (Multi Reaction 
Monitoring). In the MRM mode, a spectrometer using 
first quadrupole mass filter selects ions with the same 
mass to charge ratio (m/z) as compound of interest (par-
ent ion). In the second quadrupole, these ions undergo 
decomposition induced in a controlled manner through 
collision with neutral gas molecules. Third quadrupole 
allows to pass only ion of fragments characteristic to 
analyte of interest (daughter ions). The monitoring of 
the two specific for a given compound ion pairs (parent 
ion – daughter ion) which is called ‘ion transmission’ is 
considered sufficient for an unambiguous verification 
of the identity of the analyte and enables quantitative 
analysis based solely on mass spectrometry data. Of 
all modes of operation used in mass spectrometry, 
MRM provides the best sensitivity and reproducibility 
of quantitative determinations, while ensuring the 
specificity unattainable by using spectrophotometric 
or fluorumetric detectors.
Determination of 25(OH)D. The measurement 
of 25(OH)D in the blood by LC-MS/MS seems to be 
particularly valuable because it enables not only un-
ambiguous quantification of total serum 25(OH)D but 
also the identification of unusual or biologically less 
active metabolites, such as 3-epi-25(OH)D3 and precise 
relationships between the various isoforms and their 
metabolites in the course of a single analysis of the same 
sample [57–59]. This method allows the avoidance of 
errors related to cross-reaction of antibodies with other 
vitamin D metabolites that occur in immunochemical 
methods and the diversity of results due to individual 
recovery of vitamin D metabolites and internal stan-
dards used in HPLC methods [60–62].
Other vitamin D metabolites. Although the sensitiv-
ity of LC-MS/MS is sufficient enough for the determina-
tion of 1,25(OH)2D metabolites, such a method is not 
developed yet. Attempts are being made to determine 
vitamin D2 and D3 in tissues, particularly in adipose 
tissue [38,63] but these methods have not yet been 
introduced into routine laboratory practice. 
HPLC and GC-MS
High performance liquid chromatography (HPLC) 
and gas chromatography coupled with mass spec-
trometry (GC-MS) are techniques used to determine 
vitamin D metabolites in research projects rather 
than in routine medical diagnostics. HPLC requires 
time-consuming initial separation including liquid-
liquid extraction with organic solvents and solid 
phase extraction (SPE) for cleaning of the sample. 
A lot of efforts have been made to minimise the time-
consuming operations and to develop on line sample 
clean-up [64]. However, all purification steps prior to 
vitamin D determination can lead to false results due to 
different individual recovery of the vitamin D isoforms 
and internal standards [62]. To correctly assess the con-
centration of various vitamin D metabolites by HPLC, 
their precise separation from other structurally related 
analytes on chromatography columns is necessary. This 
is not always possible, as well as the full separation of 
a and b C3-epimers [65–66]. Although GC-MS is a very 
sensitive method, it requires an additional step using 
harmful chemicals to convert the vitamin D metabolites 
into volatile derivatives. The yield of this reaction is 
dependent on the chemical structure of the compound 
and may be not equal for all vitamin D metabolites [67]. 
The basic problem, which is not completely resolved in 
either HPLC or GC-MS, is the accurate standardisation 
of the method.
Conclusions
Total 25(OH)D is the most commonly measured and 
most useful vitamin D metabolite in clinical practice. 
The unreliability of the currently used immunochemi-
cal methods causes that LC-MS/MS from the reference, 
becomes more frequently used routine method. The 
international quality programmes and internal quality-
assurance systems improve the accurate measurement 
of vitamin D metabolites, but it is still important that 
laboratories and the medical community are aware of 
the limitations of the methods applied.
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